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Abstract
Background: Patients with severe aortic stenosis have increased levels of prothrombotic and proinflammatory
microparticles (MP), and MPs actively regulate pathological processes that lead to atherothrombotic
cardiovascular events. Shear stress is a validated stimulus of MP production, and abnormal shear stress in
aortic stenosis increases MP release in ex-vivo studies. We hypothesized that in patients with severe aortic
stenosis, percutaneous replacement of the aortic valve (TAVR) would reduce abnormal shear stress and would
decrease levels of circulating MPs.
Findings: The experimental protocol utilized flow cytometry (FC) and nanoparticle tracking analysis (NTA) to
quantify circulating plasma MP levels in aortic stenosis patients at baseline and 5 days after TAVR. The
baseline and 5 day MP counts measured by FC were 6.10⋅105 ± 1.21⋅105 MP/μL and 5.74⋅105 ± 9.54⋅104 MP/μL,
respectively (p = 0.91). The baseline and 5 day MP counts measured by NTA were 9.29⋅1013 ± 1.66⋅1013 MP/μL
and 3.95⋅1014 ± 3.11⋅1014 MP/μL, respectively (p = 0.91). When MPs were stratified by cell source, there was no
difference in pre/post TAVR endothelial, platelet, or leukocyte MP levels.
Conclusion: Levels of circulating MPs do not change acutely following TAVR therapy for aortic stenosis.
Trial registered at clinicaltrials.gov NCT02193035 on July 11, 2014.
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Background
Microparticles (MPs) are submicron membrane fragments
that impair endothelial function, promote thrombosis, and
increase the risk of cardiovascular (CV) events [1–5]. Endo-
thelial cells, platelets, and macrophages release MPs in
response to inflammatory activation and apoptotic signaling
[6–8]. Endothelial and platelet MPs circulate at elevated
levels in patients with severe aortic stenosis [9]. Shear stress
is a validated stimulus of MP production. Abnormal shear
stress in aortic stenosis increases MP release in ex-vivo
studies [7, 9]. We hypothesized that in patients with severe
aortic stenosis, percutaneous replacement of the aortic
valve (TAVR) would reduce abnormal shear stress and
would decrease levels of circulating plasma MPs.
Methods
This study included patients with severe aortic stenosis
selected for TAVR. Pre-specified exclusions are listed in
the Additional file 1. The institutional review board
approved the protocol (Comissão de Ética para Análise de
Projetos de Pesquisa—CAPPESQ / FMUSP #12079).
The protocol registration number is NCT02193035
(clinicaltrials.gov). All patients provided informed con-
sent to participate in the study. The experimental
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protocol used complementary flow cytometry (FC)
and nanoparticle-tracking analysis (NTA) to measure
MPs. FC identifies MPs based on size and based on
MP affinity for Annexin V. Annexin V binds to the
prothrombotic lipid, phosphatidylserine, on the outer
layer of the MP surface membrane. FC has a limited
ability to detect particles that are smaller than 50–100 nm,
and thus FC does not accurately quantify ultra-small MPs
[10]. Figure 1 shows representative flow cytometry data of
200nM reference sizing beads (Fig. 1a), Annexin-V positive
MPs (Fig. 1b), EDTA-treated negative controls (Fig. 1b),
and cell specific antibodies to subtype and quantify endo-
thelial, platelet, and macrophage MPs (Fig. 1c-e).
NTA identifies all MPs, including those, which do
not have phosphatidylserine on their outer surface.
Compared to FC, NTA detects MPs with a lower
limit of 50 nm size, and thus NTA has a better sen-
sitivity for ultra-small particles [11]. For this study,
MP levels were quantified at baseline and 5 days
after TAVR. Detailed methods are available in the
Additional file 1.
Results
We evaluated 15 patients that were enrolled over the
course of 12 months and excluded six patients from the
study; the reasons for exclusion were fatal stroke (1 patient),
fatal cardiogenic shock (1 patient), severe infection (3
patients), and deep venous thrombosis (1 patient). Baseline
characteristics of the 9 patients that we analyzed are
presented in Table 1.
We identified the cell origin of MPs by detecting anti-
bodies directed against endothelial cells, platelets, and
leukocytes. The flow cytometry quantification of MPs
pre- and 5-day post-TAVR is shown in Fig. 2. There was
no difference in total, endothelial cell, platelet, or macro-
phage MP counts prior to vs. 5 days after TAVR. Total
Annexin V positive MPs were 6.10⋅105 ± 1.21⋅105
pre-TAVR vs. 5.74⋅105 ± 9.54⋅104 MP/μL post-TAVR
(p = 0.91). Endothelial MPs were 2.05⋅105 ± 3.61⋅104
MP/μL pre-TAVR vs. 2.17⋅105 ± 3.38⋅104 MP/μL post-
TAVR (p = 0.73). Platelet MPs were 2.79⋅105 ± 5.02⋅104
MP/μL pre-TAVR vs. 2.74⋅105 ± 4.41⋅104 MP/μL post-
TAVR (p= 0.82). Macrophage MPs were 2.18⋅105 ± 3.49⋅104
MP/μL pre-TAVR vs. 2.07⋅105 ± 3.23⋅104 MP/μL post-
TAVR (p = 0.82).
Similar to the FC quantification, there was no dif-
ference in NTA-measured MP counts pre vs. 5 days
post-TAVR (9.29⋅1013 ± 1.66⋅1013 MP/μL pre-TAVR
vs. 3.95⋅1014 ± 3.18⋅1014 MP/μL post-TAVR, p = 0.91,
Fig. 3a). In our data set, there was no correlation
between MP levels measured by FC vs. NTA (Fig. 3b,
r2 = 0.01).
Previous investigations have demonstrated that there
is a 40 % drop in platelet count following TAVR with a
significant incidence of new thrombocytopenia [12]. In
our study, the average baseline platelet count was
220⋅109/L ± 90⋅109/L pre-TAVR, and 183⋅109/L ± 78⋅109/
L post-TAVR (p = 0.0093). Platelet counts fell by an
average of 17 %, and 44 % of patients developed
thrombocytopenia.
Fig. 1 Microparticle Flow Cytometry Quantification Method. a Side scatter profile of 200 nm silica size reference beads. b Annexin-V stained
microparticles (MP) (red) and Annexin-V stained MPs treated with EDTA (black). The SSC threshold derived from the reference beads is represented by
a dashed line (c-e) Representative flow cytometry data of cell specific antibodies to subtype and quantify endothelial, platelet, and macrophage MPs.
We defined endothelial MPs as Annexin V+/CD31+ events, platelet MPs as Annexin V+/CD41+ events, and macrophage MPs as Annexin
V+/CD45+ events. Red; specific antibody vs. black; isotype control. SSC; side scatter intensity
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Discussion
Although the sample size could be larger, our initial
results predict a futile effort to show a difference in
microparticle level pre TAVR vs. 5 days post TAVR.
Previous reports demonstrated a 16.8 % decrease in
microparticles 90 days post-TAVR [13]. We therefore
simulated adding new cases where all the additional
cases have a 20 % decrease in microparticle counts. To
calculate the likelihood of this scenario we used the
distribution of our original sample. In it, we observed a
10 % average increase in flow cytometry (FC) micropar-
ticle counts from pre-TAVR to post-TAVR with a stand-
ard deviation of 60 %. Assuming this is a normal
distribution, a 20 % decrease corresponds to half a
standard deviation less than the mean. The area of the
normal distribution below half a standard deviation is
30.9 %, which means that 30.9 % of patients would have
at least a 20 % decrease in microparticles. Therefore, the
likelihood of a scenario where all six patients present a
20 % decrease in microparticles is 30.9 % to the power
of 6, which is 0.09 %.
Next, we did the same modeling for the nanoparticle
tracking analysis (NTA). The estimated likelihood of a
scenario where all the additional patients would have a
decrease of 20 % in microparticle levels is 0.03 %. Thus,
there is less than 0.1 % chance that increasing the
sample size would have an impact on the mean change
in microparticle levels for both methods.
Moreover, if we expanded the sample size to 15
patients, and patients number 10 through 15 each had a
microparticle level that was 20 % less than their pre-
TAVR level, the p value for the difference would still be
non-significant for both methods (modeled p value for
FC: 0.51 and NTA: 0.13). Therefore, we conclude that
there is no justification to expand the study, because
doing so would not alter the results or conclusions.
In our investigations, patients with severe aortic
stenosis had higher levels of MPs compared to pub-
lished reports of MP levels in healthy patients. One
study that used similar flow cytometry methods found
3.14⋅105 MP/μL (IQR 2.27⋅105–4.45⋅105 MP/μL) total
MPs [14, 15]. Meanwhile, protocols using NTA meth-
odology report MP levels of 1–5⋅1012 MP/μL in
healthy controls subjects [11, 16]. Notably, our find-
ing that FC MP quantification varied by an order of
magnitude compared to NTA MP quantification cor-
roborates similar findings from another group [17].
An explanation for the difference in MP counts between
the two methods is that unlike FC, NTA quantifies large,
small, and ultra-small MPs, as well as both phosphatidyl-
serine positive and negative MPs [17].
Similar to previous reports, we observed marked
thrombocytopenia following the TAVR procedure [12].
Platelet consumption has the potential to increase platelet
activation and increase associated production of platelet
MPs. Despite the potential link between platelet count
and MP levels, we saw no relationship between these
two parameters in our study (correlation between
platelet count, absolute platelet decrease and FC-measured
MP, r2 = 0.02 and r2 = 0.16, respectively; correlation between
platelet count, absolute platelet decrease and NTA-
measured MP, r2 = 0.08 and r2 = 0.06; NTA, respectively).
This current clinical study demonstrates that circulat-
ing MP levels do not change acutely 5 days following
TAVR. Although the number of patients enrolled in this
study was small, based on the observed means and
standard deviation, an increase in sample size would not
change the overall conclusions. When interpreting the
negative results of this study, it is important to consider
the following points: (1) the half-life of circulating
vascular MPs is unknown, and if MPs circulate for
several days, our brief 5 day follow-up window might
prevent detection of changes in MP levels post TAVR,
(2) thrombotic or inflammatory processes may be
playing a greater role than shear stress in promoting
MP elevation in patients with aortic stenosis, (3) the
acute stress of the TAVR procedure might promote
MP production—potentially negating the reduction in
Table 1 Patient and procedure characteristics and outcomes
Characteristics N = 9
Age 84.8 ± 5.1
Male 67 %
Euroscore (Logistic) 23.5 ± 12.5 %
Peripheral artery disease 11 %
End stage renal failure 0
Creatinine (mg/dL) 1.52 ± 0.6
LV-Ao peak gradient 66.4 ± 26.2
LV-Ao mean gradient 43.9 ± 18.2






Post-TAVR LV-AO peak gradient 13.8 ± 6.4




Other Complications 11 %
LV-AO left ventricle—aortic, AVA aortic valve area, TAVR transcatheter aortic
valve replacement, TIA transient ischemic attack, MI myocardial infarction, AF
atrial fibrillation. Other complications includes arrhythmias, major bleeding
and renal failure
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MP generation achieved by replacing the stenotic valve,
and (4) the 5 day follow-up time that we chose might be
too short to enable a resetting of homeostatic systems that
activate MP release. Of note, a recent investigation
demonstrated that circulating MP levels do decrease
90 days following TAVR [13]. The later time point of
90 days may provide adequate time for recovery from the
TAVR procedure and/or resetting of homeostatic systems
that promote MP production [13, 18].
Conclusions
Our data found increased MP levels in patients with severe
aortic stenosis in comparison to reports of healthy patients.
We did not observe a reduction of MP levels in a short
follow-up of TAVR. MPs, which have prothrombotic and
proinflammatory effects, imply an increased risk of CV
events for patients with severe aortic stenosis that persists
acutely after TAVR treatment. Targetting MP generation or
effects could reduce TAVR periprocedural CV events.
Fig. 2 Flow cytometry measurement of microparticle levels before and 5 days after TAVR procedure. a Total phosphatidylserine positive
microparticles, (b) endothelial microparticles, (c) platelet microparticles, and (d) macrophage microparticles. MP; microparticles
Fig. 3 Nanoparticle tracking analysis measurement of microparticle levels before and 5 days after TAVR procedure. a Total microparticle levels.
b Flow cytometry Annexin V positive microparticle events vs. nanoparticle-tracking analysis microparticle events with linear regression comparison
between the two MP quantification methods. MP: microparticles; NTA: nanoparticle-tracking analysis
Marchini et al. Journal of Negative Results in BioMedicine  (2016) 15:7 Page 4 of 5
Additional file
Additional file 1: Detailed description of the methods. (DOCX 25 kb)
Abbreviations
FC: flow cytometry; MP: microparticle; TAVR: transcatheter aortic valve
replacement; NTA: nanoparticle-tracking analysis.
Competing interests
The authors declare no competing interest.
Authors’ contributions
JM, AAM, FT, JEK, PL and KC contributed to the design of the study and its
protocol. PL performed the TAVR procedures. JM acquired the samples,
performed the experiments. JM and KC wrote the article. KC revised the
article. JM, AAM, FT, JEK, PL and KC read the manuscript and approved the
final version.
Acknowledgments
Fundação de Amparo à Pesquisa do Estado de São Paulo (BR) provided
funding for this project to J.E.K #2013/17368-0.
Author details
1Laboratory of Genetics and Molecular Cardiology, Heart Institute, University
of São Paulo Medical School, São Paulo, SP, Brazil. 2Valvular Heart Disease
Unit, University of São Paulo Medical School, São Paulo, Brazil.
3Hemodynamics and Interventional Cardiology Service, Heart Institute,
University of São Paulo Medical School, São Paulo, SP, Brazil. 4Cardiovascular
Division, Department of Medicine, Brigham and Women’s Hospital, Harvard
Medical School, Boston, MA, USA.
Received: 24 October 2015 Accepted: 1 April 2016
References
1. Boulanger CM, Scoazec A, Ebrahimian T, Henry P, Mathieu E, Tedgui A,
Mallat Z. Circulating microparticles from patients with myocardial infarction
cause endothelial dysfunction. Circulation. 2001;104:2649–52.
2. Pfister SL. Role of platelet microparticles in the production of thromboxane
by rabbit pulmonary artery. Hypertension. 2004;43:428–33.
3. Toti F, Satta N, Fressinaud E, Meyer D, Freyssinet JM. Scott syndrome,
characterized by impaired transmembrane migration of procoagulant
phosphatidylserine and hemorrhagic complications, is an inherited disorder.
Blood. 1996;87:1409–15.
4. Huber J, Vales A, Mitulovic G, Blumer M, Schmid R, Witztum JL, Binder
BR, Leitinger N. Oxidized membrane vesicles and blebs from
apoptotic cells contain biologically active oxidized phospholipids that
induce monocyte-endothelial interactions. Arterioscler Thromb Vasc
Biol. 2002;22:101–7.
5. Viera AJ, Mooberry M, Key NS. Microparticles in cardiovascular disease
pathophysiology and outcomes. J Am Soc Hypertens. 2012;6:243–52.
6. Jimenez JJ, Jy W, Mauro LM, Horstman LL, Soderland C, Ahn YS. Endothelial
microparticles released in thrombotic thrombocytopenic purpura express
von Willebrand factor and markers of endothelial activation. Br J Haematol.
2003;123:896–902.
7. Nomura S, Tandon NN, Nakamura T, Cone J, Fukuhara S, Kambayashi J.
High-shear-stress-induced activation of platelets and microparticles
enhances expression of cell adhesion molecules in THP-1 and endothelial
cells. Atherosclerosis. 2001;158:277–87.
8. Mesri M, Altieri DC. Leukocyte microparticles stimulate endothelial cell
cytokine release and tissue factor induction in a JNK1 signaling pathway.
J Biol Chem. 1999;274:23111–8.
9. Diehl P, Nagy F, Sossong V, Helbing T, Beyersdorf F, Olschewski M, Bode C,
Moser M. Increased levels of circulating microparticles in patients with
severe aortic valve stenosis. Thromb Haemost. 2008;99:711–9.
10. van der Pol E, Hoekstra AG, Sturk A, Otto C, van Leeuwen TG, Nieuwland R.
Optical and non-optical methods for detection and characterization of
microparticles and exosomes. J Thromb Haemost. 2010;8:2596–607.
11. Dragovic RA, Gardiner C, Brooks AS, Tannetta DS, Ferguson DJ, Hole P,
Carr B, Redman CW, Harris AL, Dobson PJ, et al. Sizing and
phenotyping of cellular vesicles using Nanoparticle Tracking Analysis.
Nanomedicine. 2011;7:780–8.
12. McCabe JM, Huang PH, Riedl LA, Devireddy SR, Grondell J, Connors AC,
Davidson MJ, Eisenhauer AC, Welt FG. Incidence and implications of
idiopathic thrombocytopenia following transcatheter aortic valve
replacement with the Edwards Sapien((c)) valves: a single center experience.
Catheter Cardiovasc Interv. 2014;83:633–41.
13. Horn P, Stern D, Veulemans V, Heiss C, Zeus T, Merx MW, Kelm M,
Westenfeld R. Improved endothelial function and decreased levels of
endothelium-derived microparticles after transcatheter aortic valve
implantation. EuroIntervention. 2015;10:1456–63.
14. Jy W, Horstman LL, Jimenez JJ, Ahn YS, Biro E, Nieuwland R, Sturk A,
Dignat-George F, Sabatier F, Camoin-Jau L, et al. Measuring circulating
cell-derived microparticles. J Thromb Haemost. 2004;2:1842–51.
15. Hron G, Kollars M, Weber H, Sagaster V, Quehenberger P, Eichinger S, Kyrle
PA, Weltermann A. Tissue factor-positive microparticles: cellular origin and
association with coagulation activation in patients with colorectal cancer.
Thromb Haemost. 2007;97:119–23.
16. Gardiner C, Ferreira YJ, Dragovic RA, Redman CW, Sargent IL:
Extracellular vesicle sizing and enumeration by nanoparticle tracking
analysis. J Extracell Vesicles. 2013;2:19671.
17. van der Pol E, Coumans FA, Grootemaat AE, Gardiner C, Sargent IL, Harrison
P, Sturk A, van Leeuwen TG, Nieuwland R. Particle size distribution of
exosomes and microvesicles determined by transmission electron
microscopy, flow cytometry, nanoparticle tracking analysis, and resistive
pulse sensing. J Thromb Haemost. 2014;12:1182–92.
18. Petrov G, Regitz-Zagrosek V, Lehmkuhl E, Krabatsch T, Dunkel A, Dandel M,
Dworatzek E, Mahmoodzadeh S, Schubert C, Becher E, et al. Regression of
myocardial hypertrophy after aortic valve replacement: faster in women?
Circulation. 2010;122:S23–28.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Marchini et al. Journal of Negative Results in BioMedicine  (2016) 15:7 Page 5 of 5
